Pharmacotherapy treatment options for advanced heart failure: a review

Antoniya Kisheva; Mesut Rushid; Tanya Ivanowa; Tatyana Chalykova; Aylin Hadjiveli

doi:10.14748/ahp.v10i1.9894

Pharmacotherapy treatment options for advanced heart failure: a review

Antoniya Kisheva, Mesut Rushid, Tanya Ivanowa, Tatyana Chalykova, Aylin Hadjiveli

Abstract

Heart failure is one of the leading causes of adverse cardiac outcomes. Despite available disease-modifying therapies, about 10% of patients progress to advanced heart failure. The aim of this review is to summarize pharmacological treatment options for this phase. No large randomized trials have been conducted in patients with advanced heart failure. Most disease-modifying medications are beneficial and their use is recommended, although they are often difficult to tolerate. A personalized approach is needed.

Keywords

advanced heart failure, disease-modifying drugs

Full Text

References

Bragazzi NL, Zhong W, Shu J et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682-1690.

Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11(4):329-37.

Subramaniam AV, Weston SA, Killian JM et al. Development of Advanced Heart Failure: A Population-Based Study. Circ Heart Fail. 2022 May;15(5):e009218

Theresa A McDonagh, Marco Metra et al , 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J, 2021; 42(36):3599–3726

Rose EA, Gelijns AC, Moskowitz et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left vent

DOI: http://dx.doi.org/10.14748/ahp.v10i1.9894